DR-448 Determinants of treatment-induced mutagenesis in cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-448 Determinants of treatment-induced mutagenesis in cancer
Platinum drugs, including the most frequently used cisplatin, cause mutations in the genome, thereby contributing to the evolution of resistance …
DR-437 Multi-omics small intestinal neuroendocrine tumors
We aim to gain a deeper understanding of the pathophysiology of small intestinal neuroendocrine tumors, with a particular focus on …
DR-451 Clinical-driven discovery of noncoding cancer drivers and related transcriptomic and prognostic features
Cancer cells accumulate genetic mutations, with only a few required to trigger malignancy. Previous research has focused on coding mutations, …
DR-450 Identifying mechanisms for the ubiquitous differential gene expressions in homologous recombination deficient tumours
This project investigates why tumors with homologous recombination deficiency (HRD), a specific type of impaired DNA damage repair, show widespread changes in …
DR-445 Predicting and evaluating resistance to CDK4/6 therapies in metastatic Breast Cancer Patients
This project aims to predict the response of luminal metastatic breast cancer patients to standard of care treatment, helping to …
DR-440 Artificial Intelligence (AI) Foundation Model for Learning Novel Treatment Response Mechanisms in Large International Pan-Cancer Datasets to Improve Triple-Negative-Breast-Cancer (TNBC) Outcomes
This project uses artificial intelligence (AI) to analyze large amounts of data from cancer patients across different types of cancer, …
DR-438 Characterizing ABCB1 fusions in drug-resistant cancers
ABCB1 encodes a protein that causes chemotherapy resistance. We aim to determine what causes ABCB1 expression in drug-resistant cancers. This …
DR-444 Characterisation and in-depth analysis of the genome, transcriptome and clinical correlates of metastatic prostate cancer patients for identifying potential druggable targets
In this project we aim to use whole genome and whole transcriptome sequencing data to identify druggable targets for novel …
DR-442 Graph-based modeling of host-microbiome interactions to identify functional modules associated with cancer progression
This project aims to uncover how interactions between the human host and microbes within metastatic tumors influence cancer behavior. We …
DR-435 The role of SMC5/6 in colorectal cancer genome stability
Colorectal cancers have high levels of mutations and genome instability. While this enables tumors to become metastatic, it also may …
DR-433 Comparative flux balance analysis of metabolic networks in metastases across multiple cancer types
Tumours often exhibit different metabolic features than non-cancerous tissue. However, studying metabolism in patients has technical limitations that hold back …
DR-430 New transcriptional subgroups of colorectal cancer patients harbouring the BRAF V600E mutation
Colorectal cancer (CRC) remains the second most common cause of cancer death in the world. Approximately 12 % of CRC patients have a mutation in the …
Een complete DNA-test biedt bij patiënten met PTO de extra mogelijkheid om erachter te komen waar de kanker is begonnen. Hierdoor wordt vaak de primaire tumor toch gevonden. Daarnaast geeft de test vaak aanknopingspunten voor een gerichte behandeling.